Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (328)	12/13/1998 7:56:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1386

18 patients now enrolled in Cohort III...12 to go. Question for everyone feeling depressed here -- did you ever think a company could partner with us before cohort III was finished and simply have a clause in the contract that says they can pull out of the deal if cohort III doesn't work the way the first two did? (There's no rule against running Cohort III and Phase III simultaneously.) I'll place my bet on the probability that we don't need to finish the cohort before we get the partner signed. Remember, the "difficult" CNS head at FDA is probably leaving in January and surrogate endpoints stand to make the approval process easier than it might be otherwise. Potential partners know this information too. We also know that tax selling season ends very soon. Ariella